Attention Shareholders: Kaskela Law LLC Launches Investigation into Lucid Group Inc. (LCID, f/k/a Churchill Capital Corp. IV – CCIV) – Take Action Now!

Investigation of Lucid Group, Inc. (LCID) by Kaskela Law LLC Overview PHILADELPHIA, July 23, 2022 (GLOBE NEWSWIRE) — Kaskela Law LLC announces that it is investigating Lucid Group, Inc. (“Lucid” or the “Company”) (NASDAQ: LCID), formerly known as Churchill Capital Corp. IV (CCIV), on behalf of the Company’s long-term investors. Lucid designs, engineers, builds, and…

Read More

Attention Investors: Don’t Miss Out on Your Chance to Lead a Class Action Lawsuit with Robbins Geller Rudman & Dowd LLP for INotiv Inc. Losses!

Welcome to the World of Securities Law! Inotiv, Inc. Investor Deadline Announcement Stay Alert Investors! San Diego, July 23, 2022: Mark your calendars because the law firm of Robbins Geller Rudman & Dowd LLP has made a crucial announcement for purchasers or acquirers of Inotiv, Inc. (NASDAQ: NOTV) securities. If you made any transactions involving…

Read More

Attention Shareholders: Kaskela Law LLC Launches Investigation into World Wrestling Entertainment Inc. (WWE) Following Vince McMahon’s Retirement – Take Action Now!

Attention Shareholders: Kaskela Law LLC Launches Investigation into World Wrestling Entertainment Inc. (WWE) Following Vince McMahon’s Retirement – Take Action Now! Description: PHILADELPHIA, July 23, 2022 (GLOBE NEWSWIRE) — Kaskela Law LLC announces that it is investigating World Wrestling Entertainment Inc. (“WWE” or the “Company”) (NYSE: WWE) on behalf of the Company’s investors. On June…

Read More

Attention Investors: Don’t Miss Your Chance to Lead a Class Action Lawsuit Against IonQ Inc. and Recover Substantial Losses!

Upcoming Investor Deadline for IonQ, Inc. Securities Are You Eligible to Seek Appointment as Lead Plaintiff? SAN DIEGO, July 22, 2022 (GLOBE NEWSWIRE) – Robbins Geller Rudman & Dowd LLP Announces that purchasers or acquirers of IonQ, Inc. (NYSE: IONQ; IONQ/WS) securities between March 30, 2021 and May 2, 2022, inclusive (the “Class Period”) have…

Read More

Revolutionizing Allergy Treatment: Revelation Biosciences Inc. Releases Promising Results from REVTX-99B Phase 1b CLEAR Clinical Study

Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Disease SAN DIEGO, July 22, 2022 (GLOBE NEWSWIRE) — Revelation Biosciences Inc. (NASDAQ: REVB), a clinical-stage life sciences company, revealed groundbreaking topline data for its Phase 1b CLEAR clinical study. The study focused on evaluating the effect…

Read More